Übersetzung für "over-the-counter medicine " (Englisch → Deutsch) :

Increasingly, funding has proven to be an important part of supporting both the EU's policies to combat terrorism, and the efforts of the Member States. For actions within the EU, such funding has been provided by way of the programme Security and Safeguarding Liberties, which includes the specific programme for prevention, preparedness and consequence management of terrorism and other security-related risks and the programme for prevention of and fight against crime [27]. Over the period 2007-2013, a total amount of 745 million € has been made available to support policies to counter terrorism and organised crime. Dozens of projects to support the implementation of the EU counter terrorism strategy have been funded from these programmes, a ...[+++]nd the number of applications continues to rise.

Within the scope of this Communication, not all of the work which has been taken forward over the past five years in these broad areas can be discussed – this Communication therefore focuses on the main strategic threads under each of the four strands of the Counter-Terrorism Strategy – prevent, protect, pursue and respond.

3. The qualified person shall have acquired practical experience over at least two years, in one or more undertakings which are authorized to manufacture medicinal products, in the activities of qualitative analysis of medicinal products, of quantitative analysis of active substances and of the testing and checking necessary to ensure the quality of medicinal products.

3. The qualified person shall have acquired practical experience over at least two years, in one or more undertakings which are authorized manufacturers, in the activities of qualitative analysis of medicinal products, of quantitative analysis of active substances and of the testing and checking necessary to ensure the quality of veterinary medicinal products.

(8) experience in the United States of America and Japan shows that the strongest incentive for industry to invest in the development and marketing of orphan medicinal products is where there is a prospect of obtaining market exclusivity for a certain number of years during which part of the investment might be recovered; data protection under Article 4(8)(a)(iii) of Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products(4) is not a sufficient incentive for that purpose; Member States acting independently cannot introduce suc ...[+++]h a measure without a Community dimension as such a provision would be contradictory to Directive 65/65/EEC; if such measures were adopted in an uncoordinated manner by the Member States, this would create obstacles to intra-Community trade, leading to distortions of competition and running counter to the single market; market exclusivity should however be limited to the therapeutic indication for which orphan medicinal product designation has been obtained, without prejudice to existing intellectual property rights; in the interest of patients, the market exclusivity granted to an orphan medicinal product should not prevent the marketing of a similar medicinal product which could be of significant benefit to those affected by the condition;

To harmonize conditions for the supply of medicinal products sold over the counter or on prescription.